Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02817997 · ClinicalTrials.gov registry record
International Registry for Patients With Castleman Disease
A clinical trial of Castleman's Disease and Castleman Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT02817997: Recruiting study of Castleman's Disease and Castleman Disease, sponsored by University of Pennsylvania.
NCT02817997 is a study of Castleman's Disease and Castleman Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 1,000 participants, above the 761-participant average among 3 other Castleman's Disease trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02817997, a study of Castleman's Disease and Castleman Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
Primary Outcome
There is no intervention tested in this registry. We want determine what are common symptoms are associated with Castleman Disease. We will be examining the number of instances various symptoms such as fatigue, malaise, fever are recorded in the medical records.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-10 |
| Est. Completion | 2027-09 |
What NCT02817997 shows while recruiting
NCT02817997 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 761-participant average among 3 other Castleman's Disease trials with a reported enrollment target (31% higher).
The record links to 9 conditions, with Castleman's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02817997 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02817997 about?
NCT02817997 is a clinical study titled "International Registry for Patients With Castleman Disease". The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
What is the current status of trial NCT02817997?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2016-10. Estimated completion is 2027-09.
What conditions does trial NCT02817997 study?
This clinical trial studies the following conditions: Castleman's Disease, Castleman Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia.
Who is sponsoring clinical trial NCT02817997?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02817997 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castleman's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
RECRUITING
-
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia